Otmar Schaaf

发表

A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation

I. Waizenegger, A. Schlattl, G. Adolf, 2016, Molecular Cancer Therapeutics.

Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries

A. Eliseev, C. Nicolau, Otmar Schaaf, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target.

A. Eliseev, C. Nicolau, Otmar Schaaf, 2003, Journal of medicinal chemistry.

A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway

P. Nuciforo, Rachel Kroe-Barrett, J. Capdevila, 2021, Molecular Cancer Therapeutics.

A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques

T. Lehr, Melanie I. Titze, Otmar Schaaf, 2016, Cancer Chemotherapy and Pharmacology.

Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor

S. Knapp, M. Koegl, O. Fedorov, 2016, Journal of medicinal chemistry.

Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses

I. Waizenegger, N. Kraut, L. Frego, 2022, Oncoimmunology.

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis

G. Adolf, N. Kraut, P. Garin‐Chesa, 2015, Molecular Cancer Therapeutics.

Abstract 4522: Potent induction of a tumor-specific immune response by a cyclic dinucleotide STING agonist

T. Zichner, S. Carotta, H. Nar, 2020 .

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

E. de Stanchina, Y. Pourfarjam, N. Kraut, 2023, Nature.

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis

G. Adolf, N. Kraut, P. Garin‐Chesa, 2015, Molecular Cancer Therapeutics.

Discovery of a Chemical Probe to Study Implications of BPTF Bromodomain Inhibition in Cellular and in vivo Experiments

Julian E. Fuchs, W. Sommergruber, K. Huber, 2023, ChemMedChem.

Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.

S. Carotta, H. Nar, A. Grube, 2023, Journal of medicinal chemistry.

Discovery of novel amino-pyrimidine inhibitors of the insulin-like growth factor 1 (IGF1R) and insulin receptor (INSR) kinases; parallel optimization of cell potency and hERG inhibition

Heather Tye, Otmar Schaaf, M. Sanderson, 2015 .